ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Urinary Ferritin as an Early Indicator of Tubular Injury in Diabetic Kidney Disease: Insights from NHANES and Clinical Cohorts.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Iron-Driven Ferroptosis in Diabetic Kidney Disease: From Molecular Mechanisms to Targeted Therapeutic Translation.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Ferroptosis regulation by SGLT2 inhibitors: mechanisms and clinical benefits in diabetic kidney disease.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between iron metabolism disorders and diabetic kidney disease (DKD) and to evaluate the potential of urinary ferritin as an early marker of tubular injury in diabetic patients. Methods: This study utilized data from 1,306 diabetic patients and 1,306 propensity score-matched non-diabetic controls from the NHANES (2017-March 2020) dataset. Diabetic participants were classified into Non-DKD (n = 923) and DKD (n = 383) groups based on the urinary albumin-to-creatinine ratio (UACR). Binary logistic regression and restricted cubic spline models were used to evaluate the association between iron metabolism indicators and DKD risk. Additionally, renal tissue samples from 12 patients (6 with T2DM and 6 non-diabetic controls) undergoing nephrectomy were analyzed for iron accumulation and tubular injury markers. Clinical data from 35 T2DM patients (with and without DKD) and 20 matched healthy controls were included to assess urinary ferritin and tubular injury markers. Finally, 120 T1DM patients were stratified by disease duration to assess correlations between urinary ferritin and renal injury biomarkers. Results: Decreased serum iron (OR = 0.962, P = 0.037) and increased serum ferritin (OR = 1.001, P = 0.024) were identified as independent risk factors for DKD. Diabetic patients exhibited higher renal iron, urinary ferritin, and tubular injury markers, with significant correlations between renal iron and urinary ferritin levels. Urinary ferritin levels also increased with T1DM duration, significantly correlating with tubular injury markers. Conclusion: Impaired iron metabolism, characterized by low serum iron and high serum ferritin, is an independent risk factor for DKD. Urinary ferritin may serve as a biomarker of early tubular injury in diabetic patients, even in the absence of albuminuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.